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Abstract
Until recently it was assumed that hereditary angioedema is a disease that results exclusively from a genetic defi-
ciency of the C1 inhibitor. In 2000, families with hereditary angioedema, normal C1 inhibitor activity and protein in
plasma were described. Since then numerous patients and families with that condition have been reported. Most
of the patients by far were women. In many of the affected women, oral contraceptives, hormone replacement
therapy containing estrogens, and pregnancies triggered the clinical symptoms. Recently, in some families muta-
tions in the coagulation factor XII (Hageman factor) gene were detected in the affected persons.
Introduction
Angioedema is clinically characterized by self-limiting
episodes of marked edema involving the skin, gastroin-
testinal (GI) tract and other organs. Various forms of
acquired and hereditary angioedema (HAE) share this
clinical presentation. “Classic” HAE is associated with a
quantitative (type I) or qualitative (type II) deficiency of
C1 esterase inhibitor (C1-INH) caused by mutations of
the C1-INH gene. Until recently it was assumed that
HAE is a disease that results exclusively from a genetic
deficiency of the C1-INH. In 2000, 10 families with this
disease were described [1]. In these families a total of 36
women, but not a single man, were affected. All patients
had normal C1-INH concentration and activity with
respect to C1 esterase inhibition, ruling out both types
o fH A E( H A Et y p eIa n dH A Et y p eI I ) .T h i sh i t h e r t o
unknown disease was proposed to be termed as “heredi-
tary angioedema with normal C1 inhibitor occurring
mainly in women” or “hereditary angioedema type III.”
Subsequently, two additional families were described,
with seven affected women in one family and four in
the other [2,3]. Later on, clinical data on an additional
29 women with HAE type III were presented [4].
Because all 76 patients from the studies cited above
were women, it was assumed that the clinical phenotype
might be limited to the female sex. However, in 2006 a
family with dominantly inherited angioedema and nor-
mal C1-INH was described in which not only five
female but also three male family members were clini-
cally affected [5]. Later on, a number of further patients
with HAE type III were reported [6-10].
In 2001 the author of this article initiated a microsa-
tellite scan of the total genom (performed by Dr. C.
Hennies, Max-Delbrück Center, Berlin) in four HAE
type III families which revealed major linkage signals for
chromosomes 6 and 16 but not for chromosome 5
(unpublished data). By following a functional hypothesis
that the genetic defect might be located in the coagula-
tion factor XII (FXII) gene the factor XII gene on chro-
mosome 5 was then selectively investigated [11]. In May
2006, the causative genetic mutations in 6 index patients
of 20 families and in 22 patients of the corresponding 6
families were identified: two different missense muta-
tions have been verified which were responsible for the
disease according to the co-segregation pattern (see
below) [11]. The location of these mutations is the same
locus, 5q33-qter of the Hageman factor or coagulation
FXII gene (Online Mendelian Inheritance in Man #
610619). One mutation leads to a threonine-to-lysine
substitution (Thr309Lys) and the other to a threonine-
to-arginine substitution (Thr309Arg). The mutations
were located on the exon 9. It was also found that the
index patients of 14 further families with HAE and nor-
mal C1-INH did not show these mutations (see below)
[11]. So the 2 mutations in the factor XII gene could be
found only in some families with HAE type III and not
in others.
Hence, the following types of HAE can be differen-
tiated today: (a) hereditary angioedema due to a genetic
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type II; and (b) hereditary angioedema with normal C1-
INH (HAE type III) including hereditary angioedema
due to the two known mutations in the coagulation fac-
tor XII gene (HAE-FXII) and hereditary angioedema
with an unknown genetic cause (normal C1-INH activity
in plasma, no causative mutation in the gene coding for
C1-INH and none of the known FXII gene mutations
Thr309Lys or Thr309Arg) (HAE-unknown).
Clinical presentation
Clinical symptoms
The clinical symptoms of HAE with normal C1-INH
include: recurrent skin swellings, abdominal pain
attacks, tongue swellings, and laryngeal edema. Until
now, only a relatively small number of patients and
families have been described. In 2000, it was reported
that 36 patients exhibited relapsing skin swellings and/
or attacks of abdominal pain and/or recurrent laryngeal
edema [1]. Urticaria did not occur at any time in any of
these patients. The skin swellings lasted 2-5 days; they
affected mainly the extremities and the face, and the
trunk less frequently. The abdominal attacks likewise
lasted 2-5 days and were manifested as severe cramp-
like pains. In a more recent study, a total of 138 patients
with HAE with normal C1-INH who belonged to 43
unrelated families were examined [12]. A majority of
patients had skin swellings (92.8%), tongue swellings
(53.6%), and abdominal pain attacks (50%). Laryngeal
edema (25.4%) and uvular edema (21.7%) also were fre-
quent, whereas edema episodes of other organs were
rare (3.6%). Facial swellings and tongue involvement
occurred considerably more frequently compared with
HAE-C1-INH. The number of patients with recurrent
edema of only one organ was higher than in HAE-
C1-INH. Erythema marginatum was not observed.
Hence, HAE with normal C1-INH levels shows a char-
acteristic pattern of clinical symptoms. There are many
differences in the clinical symptoms and course of dis-
ease between this type of HAE and the classic type of
HAE, HAE-C1-INH (Appendix 1).
The clinical manifestation of HAE type III is highly
variable, and penetrance of the disease might be low;
thus, obligate female carriers, even in their seventh dec-
ade, without any clinical symptoms were observed [1,4].
Therefore, a considerable number of asymptomatic car-
riers may exist in the population.
Death by asphyxiation due to upper airway obstruction
In a patient series described in 2007[12] one female had
asphyxiated at the age of 16 during her first laryngeal
edema attack. A second female asphyxiated at the age of
36 after 10 episodes of upper airway obstruction, a third
at the age of 38 during her eighth airway attack, and a
fourth at the age of 48 after a tongue swelling.
Onset of clinical symptoms
In a series of 138 patients, the mean age at onset of the
disease was 26.8 years (SD+/- 14.9 years, range 1 to 68
years) [12]. Onset of clinical symptoms occurred in the
first decade of life in 11 (8%) patients, in the second
decade in 60 (43.5%) patients, in the third decade in 22
(15.9%) patients, and later in 45 (32.6%) patients. Hence,
the number of patients with disease onset in adulthood
was significantly higher in HAE with normal C1-INH
compared with HAE-C1-INH.
Potentially provoking factors
1. Role of estrogens
In many women clinical symptoms either begin or are
exacerbated following the intake of oral contraceptives
or hormone replacement therapy, or during pregnancy
[1-4]. This observation has led to the assumption that
the clinical manifestation of this new type of HAE is
estrogen-dependent. Binkley and Davis observed patients
with typical symptoms of recurrent angioedema that
were restricted to conditions of high estrogen levels
and thereby created the conception of an “estrogen-
dependent” or “estrogen-associated” HAE [2,13]. How-
ever, in an analysis of 228 angioedema patients receiving
oral contraceptives or hormone replacement therapy, it
was demonstrated that in only 24 (62%) of 39 women
with HAE type III were the clinical symptoms induced
or exacerbated after starting oral contraceptives or hor-
mone replacement therapy; correspondingly, 15 (38%) of
39 women tolerated exogenous estrogens without any
influence on their disease [4]. Almost identical numbers
were observed with respect to women diagnosed with
HAE-C1-INH. These results show that estrogens play a
role in both conditions and that the negative influence
of estrogens is not a specific sign for HAE type III [14].
2. Angiotensin-converting enzyme inhibitors
It is well known that angiotensin-converting enzyme
inhibitors (ACE-I) are associated with the occurrence of
angioedema in about 0.7% of individuals who receive
this medication [15,16]. It has been reported that ACE-I
can induce an exacerbation of symptoms in patients
with HAE-C1-INH [17]. A 60-year-old man from a
family with HAE with normal C1-INH was reported
who has had arterial hypertension since age 30 and had
four tongue swellings following treatments with capto-
pril and enalapril [5]. The last episode occurred when
the patient received only hydrochlorothiazide and meto-
prolol. The patient has had no other symptoms of HAE.
This observation demonstrates that ACE-I might have a
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III shares this feature with HAE-C1-INH. This state of
affairs points to an important role of bradykinin in the
pathogenesis of HAE type III (see below).
3. Angiotensin II type 1 receptor antagonists
Two unrelated patients with preexisting HAE type III
were described who experienced severe exacerbation of
symptoms associated with using angiotensin II type 1
receptor antagonists (angiotensin II type 1 receptor
blockers, ARB) [18]. A possible pathogenetic relation-
ship between the underlying disease and the drug-
associated angioedema was suggested.
Gender
The disease has been observed predominantly by far in
women [1-4,11,12]. In two families, however, the exis-
tence of clinically unaffected male carriers has been
deduced [2,3]. In 2006 a family with dominantly inher-
ited angioedema and normal C1 inhibitor was described
in which not only five female but also three male family
members were clinically affected [5]. Later on further
male patients with HAE type III were reported, among
them also patients with HAE-FXII [8,12]. The familial
angioedema observed by Gupta et al.[19] in three broth-
ers appears to be a HAE with normal C1-INH in men;
h o w e v e r ,ap o s s i b l yr e c e s s i v ei n h e r i t a n c ep a t t e r na n da
favorable response to treatment with antihistamines may
indicate that the three brothers’ condition is different
from that of the family we observed [5]. In a study of 25
patients with idiopathic nonhistaminergic angioedema,
Cicardi et al.[20] mentioned that four of these patients
had affected relatives. In at least three of these families,
all affected individuals were male.
Inheritance
Within the 43 families described in 2007[12], between
two and 10 members per family were affected. The
examination of the pedigrees of the 43 families revealed
that 2 successive generations were affected in 30
families, 3 successive generations were affected in 9
families, and 4 successive generations were affected in 4
families. These results support the assumption of a
dominant inheritance pattern.
Genetic results
C1-INH activity and C4 in plasma were normal in most
patients and slightly decreased in a small proportion of
patients [12,14]. Therefore, right from the beginning it
seemed to be improbable that the cause of the disease
would be a mutation in the C1-INH gene. Binkley and
Davis [2] found no abnormalities in either the 5’ regula-
tory region or the coding sequences of the C1-INH gene
in affected individuals. In four of our affected patients
we also looked for mutations in the C1-INH gene and
did not find any. Binkley and Davis also sequenced the
5′ regulatory region of factor XII gene because it con-
t a i n sak n o w ne s t r o g e nr e s p o n s ee l e m e n t .H o w e v e r ,
they found no abnormalities in that region.
In 2006, a genetic examination revealed new insight
into HAE type III (see above) [11]. It was hypothesized
that an abnormal coagulation factor XII molecule may
lead to inappropriate activation of the kinin-forming
cascade of which factor XII is a major constituent.
Therefore, a search for mutations in the factor XII
(Hageman factor) (F12) gene was performed [11]. In 20
unrelated patients with HAE type III the 14 exons and
splice junctions of the F12 gene were screened by PCR
amplification and bidirectional sequencing. Two differ-
ent non-conservative missense mutations were identified
in exon 9. Both mutations are located in exactly the
same position, namely in the second position of
the codon (ACG) encoding amino acid residue 309 of
t h em a t u r ep r o t e i n ,at h r e o n i n er e s i d u e .O n em u t a t i o n ,
encountered in five unrelated patients, results in an
AAG triplet encoding a lysine residue (Thr309Lys). The
other mutation, observed in one patient, predicts a
threonine-to-arginine substitution (Thr309Arg). Thus,
with respect to both mutations, the wild-type threonine
residue is substituted by a basic amino acid residue. In
accordance with the dominant inheritance pattern of the
disease, patients are heterozygous for the respective
mutations. Neither of the two mutations was detected in
145 healthy control individuals in this control panel. In
six of the 20 families, 20 individuals, all female, were
clinically diagnosed with HAE with normal C1-INH. All
these 20 women were found to be heterozygous carriers
of either the Thr309Lys or the Thr309Arg mutation.
Two additional women carried the Thr309Lys mutation
but have not experienced any angioedema symptoms up
to now. Finally, there were eight male heterozygous car-
riers of a missense mutation of Thr309, all symptom-
free [11].
Until now, the Thr309Lys mutation has been reported
in 11 families surveyed in our Angioedema Outpatient
Service [11,14] and in 8 families studied by other
authors, one family by each of them [6-8,21-25].
Potential role of the mutations in the FXII gene in
HAE-FXII
The predicted structural and functional impact of the
mutations in the factor XII gene, their absence in
healthy controls, and their co-segregation with the phe-
notype all provide strong support for the idea that these
mutations cause disease. The remarkable observations
that (1) two different mutations seen in patients but not
controls both affect the identical DNA position, and (2)
both lead to substitution of the wild-type threonine
Bork Allergy, Asthma & Clinical Immunology 2010, 6:15
http://www.aacijournal.com/content/6/1/15
Page 3 of 8residue by a positively charged residue, lend further sup-
port to the assumption that these mutations play a dis-
ease-causing role.
It is not clear how the mutations in the FXII gene
cause HAE-FXII, i.e. the tendency to develop recurrent
and self-limiting edema attacks in various organs. There
are several arguments for the assumption that the kallik-
rein-kinin system (KKS) also known as the “contact sys-
tem” or “contact activation system” might be involved in
the pathogenesis: (a) the causative mutations are in the
FXII gene, and FXII is part of KKS; (b) KKS activation
with the release of bradykinin at the end of the cascade
is known to cause the acute attacks of HAE due to C1-
INH deficiency; and (c) corticosteroids and antihista-
mines are therapeutically ineffective for the treatment of
swelling in HAE-FXII, therefore, histamine does not
seem to play a major role in HAE-FXII.
Coagulation factor XII is a serine protease circulating
in human plasma as a single-chain inactive zymogen at
a concentration of approximately 30 μg/ml [26-29].
Upon contact with negatively charged surfaces, factor
XII is activated by autoactivation and by plasma kallik-
rein, which itself is generated from prekallikrein by acti-
vated factor XII, high-molecular weight kininogen
serving as a co-factor for reciprocal activation of factor
XII and prekallikrein. Factor XII is a typical mosaic pro-
tein: following a leader peptide of 19 residues, the
mature plasma protein consists of 596 amino acids and
is organized in an N-terminal fibronectin type-II
domain, followed by an epidermal growth factor-like
domain, a fibronectin type-I domain, another epidermal
growth factor-like domain, a kringle domain, a proline-
rich region, and the C-terminal catalytic serine protease
domain [27]. The described amino acid substitutions are
located in the poorly characterized proline-rich region
of factor XII [11]. This region appears to play some role
in the binding of factor XII to negatively charged sur-
faces [28,29]. Thus, one may speculate that those muta-
tions may influence mechanisms of contact activation
and may eventually inappropriately facilitate factor XII
activation.
A report of patients with HAE-FXII demonstrated a
more than 4-fold increase in FXIIa amidolytic activity
on S-2302 compared with healthy controls [6]. The
increased enzymatic activity was blocked completely by
2 mM PCK, and the report stated that PCK specifically
inhibits FXII activation in human plasma. Based on
these findings, it was suggested that the FXII Thr309Lys
mutation (referred to as Thr328Lys by adding the leader
protein) is a gain-of-function mutation that markedly
increases FXII amidolytic activity but that does not alter
FXII plasma levels [6]. In a more recent study, elements
of the kallikrein-kinin system and the downstream-
linked coagulation, complement, and fibrinolytic systems
in the plasma of six patients with HAE caused by the
Thr309Lys mutation and healthy probands were exam-
ined [30]. The mean FXII clotting activity was 90% in
patients with the FXII mutation and the concentration
of FXIIa was 4.1 ng/ml; this did not differ from healthy
probands. Mean prekallikrein amidolytic activity and
high-molecular weight kininogen clotting activity were
130% and 144%, respectively, both higher than in
healthy probands. The mean kallikrein-like activity of
the HAE patients was 11.4 U/l and did not differ from
the healthy probands. There was no difference in FXII
surface activation by silicon dioxide or in kallikrein-like
activity with and without activation by dextran sulfate.
Contrary to the results of the study mentioned before
[6] no indication that the Thr309Lys mutation causes a
“gain-of-function” of FXIIa was observed in this investi-
gation. Hence, the functional role of the observed FXII
gene mutations in HAE type III still remains unclear.
The mediator responsible for edema formation in
HAE type III is not known. However, consider the fol-
lowing facts: (a) there are many similarities concerning
clinical symptoms of hereditary angioedema types I and
III; (b) the percentages of women whose disease is nega-
tively affected by estrogen-containing medications is
similar in both conditions; (c) angiotensin-converting
enzyme inhibitors and angiotensin II type 1 receptor
antagonists may lead to an increase in frequency and
severity of attacks in HAE type III (according to the
observations mentioned above) similar to HAE due to
C1 inhibitor deficiency (HAE type I and II); and (d) the
response to antihistamines and corticosteroids is lacking,
at least in the patients reported up to now. These facts
permit the speculation that edema formation in HAE
type III may also be related to the kinin pathway. It is
possible that bradykinin is the most important mediator
in HAE type III, similar to HAE type I and II.
Diagnosis
Up to now the clinical diagnosis of “hereditary angioe-
dema with normal C1 inhibitor” has required that
patients have the above-mentioned clinical symptoms,
one or more family members also affected with these
symptoms, the exclusion of familial and hereditary
chronic urticaria with urticaria-associated angioedema,
and normal C1-INH activity and protein in plasma. The
diagnosis “hereditary angioedema with coagulation fac-
tor XII gene mutation” (HAE-FXII) requires the corre-
sponding demonstration of the mutation. Until now
there is no further laboratory test which could confirm
the diagnosis “HAE type III”.
The question whether there are sporadic, non-familial
cases cannot be answered satisfyingly today. Sporadic
cases of HAE-FXII with no mutations in the FXII gene
in the close relatives have not been reported until now.
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sible at present since there are no laboratory tests avail-
able to confirm the diagnosis of this subtype of HAE III
(see also under “idiopathic angioedema”, see below).
Differential diagnosis
The most important differential diagnosis of HAE type
III are other types of recurrent angioedema. Angioe-
dema is a clinical sign that belongs to various clinical
entities. Some of them are due to a hereditary or
acquired C1-INH deficiency such as HAE types I and II
and acquired angioedema due to C1-INH deficiency.
Other types are not associated with a C1-INH defi-
ciency. Besides HAE with normal C1-INH (HAE type
III) they include angioedema due to ACE-I and ARB,
angioedema associated with an urticaria, allergic or non-
allergic angioedema caused by insect stings, food or cer-
tain drugs, and idiopathic angioedema.
(a) Hereditary angioedema due to C1 inhibitor deficiency
In HAE, edema of the skin, abdominal pain attacks, and
life-threatening laryngeal edema are the most frequently
encountered symptoms, their relation being 70:54:1
[31,32]. Skin swellings occur most frequently in the
extremities and less frequently on the face or on other
body sites [33]. Abdominal attacks of HAE are mostly
characterized by pain, vomiting and diarrhea. They are
caused by transient edema of the bowel wall, leading to
partial or complete intestinal obstruction, ascites, and
hemoconcentration. C1-INH activity and C4 protein are
low in plasma. The features of HAE type III that serve
to differentiate it from hereditary angioedema due to
C1-INH deficiency are listed is Appendix 1.
(b) angioedema due to angiotensin converting enzyme
inhibitors and angiotensin-II receptor blockers
ACE-I are commonly used for the treatment of hyper-
tension and congestive heart failure. Recurrent angioe-
dema as a complication of therapy with ACE-I is well
described in the literature [15,16]. Most often it occurs
as a well-demarcated swelling of the tongue, lips, or
other parts of the face. Edema of the mucous mem-
branes of the mouth or throat are less frequently. Iso-
lated dysphagia or edema of the gastrointestinal tract
are rare. Angioedema of the upper respiratory tract can
result in acute respiratory distress, airway obstruction
and, rarely, death. Angioedema due to ACE-I often
occurs within one week after starting the medication.
Numerous patients, however, have been reported in
whom the first angioedema occurred after some weeks
or months or even years after starting treatment with
ACE-I. Patients with a history of recurrent idiopathic
angioedema may be at increased risk for developing
ACE-I induced angioedema. The ARB which exert their
antihypertensive effect through specific blockade of the
angiotensin II via blockade of the angiotensin subtype 1
receptor appears to have a much lower incidence of
recurrent angioedema. The history of hypertension or
congestive heart failure and the onset of recurrent
angioedema following the treatment with ACE-I and the
non-familial occurrence separates ACE-I-induced
angioedema clearly from HAE type III.
(c) Urticaria-associated angioedema
More than 50% of patients with a chronic urticaria have
o n eo rm o r ee p i s o d e so fa n g i o e d e m ai nt h e i rh i s t o r yo f
urticaria. So in those patients angioedema seems to be a
part of chronic urticaria [34]. In most patients by far,
chronic urticaria and urticaria-associated angioedema
respond to antihistamines. Patients with HAE type III
have only angioedema and no urticaria as far as it is
known today. Furthermore HAE type III usually does
not respond to antihistamines. So the differentiation of
urticaria-associated angioedema from HAE type III can
clearly be made by patients’ history and by clinical
features.
(d) Allergic or non-allergic angioedema caused by insect
stings, food, certain drugs, or infections
Insect stings, the intake of certain food or certain drugs
may lead to allergic (anaphylactic) or nonallergic (ana-
phylactoid) reactions [35,36]. Mainly they include urti-
caria, angioedema, and circulatory reactions due to a
drop of blood pressure reaching from faintness to severe
shock. Each of these symptoms may occur alone or they
may occur together in various combinations. In this
context one or more episodes of isolated angioedema
may occur, mostly as a facial swelling. These are reactive
swellings, i.e. swellings with a recognizable trigger. They
do not occur without a trigger. Therefore they can be
clearly separated from HAE type III.
(e) Idiopathic angioedema
This type of angioedema is poorly understood. Already
the definition of idiopathic angioedema varies consider-
ably. Some authors include urticaria-associated angioe-
dema [34], others restrict the diagnosis of idiopathic
angioedema to patients with recurrent angioedema with-
out an urticaria. It is a fact that there is a number of
patients with recurrent angioedema which cannot be
classified to one of the types of recurrent angioedema
mentioned above, despite an extensive diagnostic
workup. Probably, recurrent idiopathic angioedema
without urticaria is not a single disease. Three types of
idiopathic angioedema were proposed: one type in
which patients responded to antihistamines (idiopathic
histaminergic angioedema), another one without a
response to antihistamines but response to tranexamic
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third type not responding to both antihistamines and
tranexamic acid [20,35].
HAE type III is defined as a hereditary disease; in all
families reported until now more than one individual
per family were affected. Whether there are sporadic,
nonfamilial cases is presently not known. Patients with
HAE-FXII and no other family member with mutations
in the FXII gene would have a new mutation. Such
patients have not been reported until now. Whether
some of the patients with idiopathic angioedema are
solitary cases of HAE-unknown cannot be proven since
at present there are no labaratory tests available for
diagnosing this subtype of HAE type III.
Management
Treatment of Acute Attacks
Until now, acute attacks of HAE type III were treated
with a C1-INH concentrate, icatibant, corticosteroids,
antihistamines, and adrenalin (Table 1). In one study, 7
patients with HAE-XII received a C1-INH concentrate
(Berinert®, CSL Behring, Inc., Marburg, Germany) for 63
angioedema attacks [14]. One patient who received this
agent once for an abdominal attack reported that it was
not effective. In the other 6 patients, the agent was very
or moderately effective. Recently, 3 patients with HAE
type III were reported who were treated with icatibant,
a bradykinin B2 receptor antagonist used in Europe for
acute attacks of HAE-C1-INH [37]. Time to resolution
of symptoms was 1 to 2 hours in the 3 treated attacks.
In one attack the symptoms recurred after 6 hours and
necessitated a second injection of icatibant. In 23 of our
patients with HAE type III [1], previous angioedema
attacks had been treated with corticosteroids (at a
dosage of 100-250 mg one or more times daily) and
antihistamines; however, this treatment was ineffective
in all 23 cases. Likewise, in other studies [10,14,38]
patients with HAE type III did not respond to corticos-
teroids and antihistamines.
Prophylactic Treatment
Progesterone, danazol, and tranexamic acid have been
used prophylactically to prevent angioedema attacks
(Table 1). In one study, 8 patients with HAE-FXII
received a progesterone-containing and estrogen-free
oral contraceptive [14]. Seven of these patients took des-
ogestrel, which is a progestagen, for 1 to 6 years, for a
total of 27 years. One of these 7 patients was switched
to an implant with etonogestrel for 3 years. The remain-
ing woman received injections of medroxyprogesteron
for 3 years. The 8 women were symptom-free during
progesterone treatment. One woman with HAE-FXII
received danazol (200 mg), an attenuated androgen,
daily for 12 years [14]. While on treatment, she was
symptom free. During these 12 years, she discontinued
danazol twice. Each cessation of treatment was followed
by a series of severe abdominal attacks, tongue swel-
lings, and skin swellings, and each time the patient
resumed treatment. To date, the patient has had no side
effects from danazol treatment. A second patient who
received danazol (100 mg) daily for 6 years for severe
HAE symptoms was also free of symptoms during treat-
ment. The dose was subsequently tapered and discontin-
ued; during the 2 years between discontinuation and the
present, no HAE symptoms were observed [14]. Other
studies [3,38,39] have also shown an improvement in
symptoms in patients with HAE type III during treat-
ment with danazol. One woman with HAE-FXII who
started tranexamic acid therapy (4 g/d) has had no
attacks with this treatment regimen [14].
Conclusions
Hereditary angioedema with normal C1 inhibitor (HAE
type III) is clinically characterized by recurrent angioe-
dema affecting the skin, gastrointestinal tract, and lar-
ynx. Skin swellings are the most frequent symptoms of
HAE type III. Most often they occur on the face, less
frequently at the extremities, and only in rare cases at
Table 1 Treatments in hereditary angioedema with
normal C1-INH (HAE type III) as reported up to now
Treatment effective
(no. of patients;
[reference])
Treatment not
effective
(no. of patients;
[reference])
Acute attacks
C1-INH
concentrate
6 [14] 4 [1]
1 [14]
Icatibant 3 [37] 0
Corticosteroids 0 23 [1]
1[ 7 ]
1 [22]
Antihistamines 0 23 [1]
1[ 7 ]
1 [21]
1 [22]
Adrenalin 0 1 [21]
Prophylaxis
Androgens 2 [1] 0
1[ 3 ]
1 [38]
Tranexamic acid 1 [10] 2 [1]
1 [14] 1 [37]
Progesterone 1 [5] 0
1 [10]
8 [14]
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attacks are less frequent symptoms. Laryngeal edema is
rare. Death by asphyxiation as a result of attacks of
upper airway obstruction has been observed. Women
are more often affected than men. In some women the
clinical symptoms of HAE type III occur exclusively in
periods of oral contraceptives, hormonal replacement
therapy or pregnancies, indicating that estrogens may
have a considerable influence on the phenotypical dis-
ease expression. Only limited data on the molecular
basis of HAE type III are currently available. In some
families with HAE and normal C1-INH, mutations in
the FXII gene have been found in the affected patients.
The cosegregation of these mutations with the disease
phenotype demonstrates the causative role of the muta-
tions. Several treatment options are available for HAE
type III, including C1-INH agents, progesterone, dana-
zol, and tranexamic acid.
Abbreviations
ACE-I: angiotensin-converting enzyme inhibitors; ARB: angiotensin II type 1
receptor blockers; C1-INH: C1 esterase inhibitor; DNA: deoxyribonucleic acid;
FXII: coagulation factor XII; HAE: hereditary angioedema; HAE-C1-INH:
hereditary angioedema due to C1 inhibitor deficiency; HAE-FXII: hereditary
angioedema due to mutations in the factor XII gene; KKS: kallikrein-kinin
system.
Appendix 1. Features of hereditary angioedema with normal C1-INH
that serve to differentiate it from hereditary angioedema due to C1-
INH deficiency
￿ Patients have normal C1-INH protein and activity.
￿ Mainly women are clinically affected.
￿ The number of children already affected before the age of 10 years is low.
Clinical symptoms start in adulthood in more patients than in hereditary
angioedema due to C1-INH deficiency.
￿ There are more disease-free intervals during the course of the disease.
￿ Symptoms are less frequent compared with hereditary angioedema due to
C1-INH deficiency.
￿ Facial swellings, mainly lip swellings, are relatively more frequent.
￿ The tongue is considerably more often affected: Recurrent tongue swelling
is observed in many patients and is a cardinal symptom of the condition.
￿ Many patients have only skin swellings.
￿ Many patients have only recurrent skin swellings and tongue swellings.
￿ Abdominal attacks are less frequent.
￿ Suffocation may be preceded and caused by a tongue swelling.
￿ There is no erythema marginatum (gyrated erythematous rash) as is highly
characteristic of HAE due to C1-INH deficiency.
￿ Hemorrhages into skin swellings were observed in hereditary angioedema
with normal C1-INH.
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